ロード中...
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Gemtuzumab ozogamicin (GO, Mylotarg(®)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7460695/ https://ncbi.nlm.nih.gov/pubmed/32781546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21165626 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|